According to MedCity News, a third patient dosed with AT132 during the ASPIRO trial has died. The Phase 1/2 clinical trial tested the efficacy, safety, and tolerability of AT132 for…
Recently, the Michael J. Fox Foundation (MJFF) awarded $1.4 million in funding for Modag, a drug developer whose solutions treat patients with neurodegenerative diseases. In fact, says Parkinson's News…
Arrowhead Pharmaceuticals has began dosing patients in its AROENaC1001 trial, which evaluates ARO-ENaC as a treatment for cystic fibrosis. 54 patients will be treated with this therapy in an effort…
Today, American Gene Technologies (AGT) announced that they will soon be beginning a Phase 1 clinical trial for AGT103-T, a potential treatment for HIV. The unique gene therapy, developed…
In a recent press release, Swedish biotechnology company Active Biotech announced that the first patient in their Phase 1b/2a clinical trial received a dose of tasquinimod. The trial will…
The HEALY ALS Platform Trial, being conducted by Biohaven Pharma, has begun enrolling patients. This study is intended to test the efficacy of three treatments on amyotrophic lateral sclerosis (ALS),…
Just because we are staying home to avoid COVID-19 doesn't mean the medical field has stopped! In fact, many doctors are more determined than ever to improve patient outcomes.…
As COVID-19 continues to spread, the rush for a treatment or cure continues. Today, on August 4, there are 18.2 million diagnosed cases worldwide, with an associated 692,000 deaths.…
Over the last few days, the American Society of Retina Specialists (ASRS) held their Annual Virtual Meeting; coined "2020 Virtual Sessions," professionals converged online to share insights into ophthalmological…
While medications and surgery can both improve gastroparesis symptoms, many patients still struggle with finding the right treatment. However, a new medication might soon help: tradipitant. In a study published…
According to SeekingAlpha, biotechnology company QED Therapeutics recently announced that the first pediatric patient was dosed in the PROPEL 2 trial. The mid-stage trial, which is testing the investigational…
Recently, pharmaceutical company RIBOMIC announced that the first patient was dosed in their Phase 1 clinical trial. Ultimately, the trial is meant to determine whether RBM-007 could be an effective…
According to a recent press release from Albireo Pharma, the first participant has enrolled in the BOLD trial. The BOLD trial, which stands for Biliary atresia and the use…
Around 10 million people worldwide are living with Parkinson's disease, a progressive nervous system disorder impacting movement. While there are many current and proposed treatments, the medical community continues…
After three years, patients with Leber hereditary optic neuropathy (LHON) who had been treated with LUMEVOQ experienced sustained safety and efficacy. According to a press release from GenSight Biologics,…
In 2019, Alnylam Pharmaceuticals received FDA approval for Givlaari, the first RNAi therapy for patients with acute hepatic porphyria. Although some were initially worried about the therapy's safety and…
Scientists from the Universities of Edinburgh and Cambridge in collaboration with a research center in Germany have analyzed a DNA-damaging chemical that has given scientists a better understanding of the…
If you could take a vaccine to prevent disease progression, would you? Well, researchers recently tested the efficacy of such a vaccine for patients with Parkinson's disease. The experimental and…
This morning, SynAct Pharma AB announced in a press release that they began a Phase II clinical trial to determine the efficacy and safety of AP1189 on treating patients with…
This week, UbiVac and Bristol Myers Squibb announced their clinical trial collaboration in a Biospace press release. The two companies, in a Phase 1b trial, look to study whether combining…
Currently, up to 5% of American citizens have nonalcoholic steatohepatitis (NASH), a liver disease resulting in damage and inflammation. But there's no approved treatments, presenting an unmet need in…
According to BioSpace, biotechnology company Argenx recently announced positive results from their Phase III ADAPT clinical trial. The company, who seeks to find breakthroughs in immunology and translate them…
It all began with an email in 2019. Matt Might, director of the Hugh Kaul Precision Medicine Institute, shot his thoughts over to neurosurgery resident Matt Davis, whose 3-year-old son…
Why are rare diseases so difficult to study? Is it just their rarity? Or is it also industry challenges? Unfortunately, industry has a lot to do with it. Clinical Trial…
Big development for those in the primary hyperoxaluria type 1 (PH1) community! Alnylam Pharmaceuticals just announced that its Phase 3 study of lumasiran, an investigational therapy for the treatment of primary…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
